Current options for the treatment of impetigo in children

Bibliography

• SLADDEN MJ, JOHNSTON GA: Common skin infections in children. Br. Med. J. (2004) 329:95–99.
   PubMed Web of Science ®Google Scholar
• RESNICK SD: Staphylococcal and streptococcal skin infections:pyodermas and toxin-mediated syndromes. In: Textbook of Pediatr. Dermatol J Harper, A Oranje, N Prose (Eds), Blackwell Science Ltd, Oxford, UK (2000) 369–377.
   Google Scholar
• ••An excellent clinical overview.
   Google Scholar
• LEE P, ZIPOLI M, WEINBERG A, SWARTZ M, JOHNSON R: Pyodermas: staphylococus aureus, streptococcus, and other Gram-positive bacteria. In: Fitzpatricki Dermatology in general medicine, I Freedberg, A Eisen, K Wolff, K Austen, L Goldsmith, S Katz (Eds), McGraw-Hill, New York, NY, USA (2003)1856–1867.
   Google Scholar
• ••A superb detailed clinical account.
   Google Scholar
• ERIKSEN NH, ESPERSEN F, ROSDAHL VT, JENSEN K: Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol Infect. (1995) 115(1):51–60.
   PubMed Web of Science ®Google Scholar
• KONING S, VAN BELKUM A, SNIJDERS S et al.: Severity of nonbullous Staphylococcus aureus impetigo in children is associated with strains harboring genetic markers for exfoliative toxin B, Panton-Valentine leukocidin, and the multidrug resistance plasmid pSK41../. Chit. Microbic] (2003) 41(7):3017–3021.
   Google Scholar
• ONG PY, OHTAKE T, BRANDT C et al.: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl. J. Med. (2002) 347(15):1151–60.
   PubMed Web of Science ®Google Scholar
• FRITSCH P, ELIAS P. VARGA J: The fate of Staphylococcal exfoliatin in newborn and adult mice. BE J. Dermatol (1976) 95(3):275–284.
   PubMed Web of Science ®Google Scholar
• AMAGAI M, MATSUYOSHI N, WANG ZH, ANDL C, STANLEY JR: Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat. Med. (2000). 6(10:1275–1277.
   PubMedGoogle Scholar
• •An important paper on the action of ETs.
   Google Scholar
• RESNICK S, FRITSCH P, ELIAS P: The staphylococcal scalded skin and toxic shock syndromes. In: Physiology, Biochemistry and Molecular Biology of the Skin. L Goldsmith (Ed.), Oxford University Press, Oxford, UK (1991).
   Google Scholar
• MONDAY SR, VATH GM, FERENS WA et al.: Unique superantigen activity of staphylococcal exfoliative toxins. Immunol (1999) 162(8):4550–4559.
   Google Scholar
• ••One side of the current controversy on theproperties of ETs.
   Google Scholar
• FEINGOLD DS: Staphylococcal and streptococcal pyodermas. Semin. Dermatol (1993) 12(4):331–335.
   PubMedGoogle Scholar
• HLADY WG, MIDDAUGH JP: An epidemic of bullous impetigo in a newborn nursery due to Staphylococcus aureus: epidemiology and control measures. Alaska Med. (1986) 28(4):99–103.
   PubMedGoogle Scholar
• HOEGER PH, ELSNER P: Staphylococcal scalded skin syndrome: transmission of exfoliatin-producing Staphylococcus aureus by an asymptomatic carrier. Pediatr: Infect. Dis. J. (1988) 7(5):340–342.
   PubMedGoogle Scholar
• DANCER SJ, SIMMONS NA, POSTON SM, NOBLE WC: Outbreak of staphylococcal scalded skin syndrome among neonates. J. Infect. (1988) 16(0:87–103.
   PubMedGoogle Scholar
• JOHNSTON GA: Treatment of bullous impetigo and the staphylococcal scalded skin syndrome in infants. Expert Rev Anti. Infect. Ther. (2004) 2(3):439–446.
   PubMedGoogle Scholar
• JOHNSTON GA, GHURA HS, CARTER E, GRAHAM-BROWN RA: Neonatal erythema multiforme major. Clin. Exp. Dermatol (2002) 27(8):661–664.
   PubMed Web of Science ®Google Scholar
• HOEGER PH: Antimicrobial susceptibility of skin-colonizing S. aureus strains in children with atopic dermatitis. Pediatr. Allergy Iminunol (2004) 15(5):474–477.
   Google Scholar
• KONING S, VAN DER WOUDEN JC: Treatment for impetigo. Br. Med. J. (2004) 329(7468):695–696.
   PubMedGoogle Scholar
• KONING S, VERHAGEN AP, VAN SUIJLEKOM-SMIT LW, MORRIS A, BUTLER CC, VAN DER WOUDEN JC: Interventions for impetigo. Cochrane Database Syst. Rev (2004) (2):CD003261.
   Google Scholar
• ••An excellent evidence-based review.
   Google Scholar
• KONING S, VAN SUIJLEKOM-SMIT LW, NOUWEN JL: Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. Br. Med. J. (2002) 324(7331):203–206.
   PubMedGoogle Scholar
• COOKSON BD: The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J. Antimicrob. Cheinother. (1998) 41(1):11–18.
   PubMed Web of Science ®Google Scholar
• McLINN S: A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J. Am. Acad. Dermatol (1990) 22(5 Pt 1):883–885.
   Google Scholar
• BRADLEY SF, RAMSEY MA, MORTON TM, KAUFFMAN CA: Mupirocin resistance: clinical and molecular epidemiology. Infect. Control. Hosp. Epidemiol (1995) 16(6):354–358.
   PubMed Web of Science ®Google Scholar
• KATZ BE, FISHER AA: Bacitracin: a unique topical antibiotic sensitized Am. Acad. Dermatol (1987) 17(6):1016–1024.
   PubMed Web of Science ®Google Scholar
• GOLLHAUSEN R, ENDERS F, PRZYBILLA B, BURG G, RING J: Trends in allergic contact sensitization. Contact Dermatitis (1988) 18(3):147–154.
   PubMed Web of Science ®Google Scholar
• HEDRICK J: Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr. Drugs (2003) 5\(Suppl. 1):35–46.
   Google Scholar
• AMAYA-TAPIA G, AGUIRRE-AVALOS G, ANDRADE-VILLANUEVA J et al.: Once-daily azithromycin in the treatment of adult skin and skin-structure infections. Antimicrob. Chemother. (1993) 31(Suppl. E):129–135.
   Google Scholar
• FEDER HM Jr, POND KE: Addition of rifampin to cephalexin therapy for recalcitrant staphylococcal skin infections-observation. OM Pediatr (Ph/la) (1996) 35(4):205–208.
   Google Scholar
• ZAFAR AB, BUTLER RC, REESE DJ, GAYDOS LA, MENNONNA PA: Use of 0.3% triclosan (Bacti-Stat) to eradicate an outbreak of methicillin-resistant Staphylococcus aureus in a neonatal nursery. Am. J. Infect. Control. (1995) 23(3):200–208.
   Google Scholar
• HENKEL T, FINLAY J: Emergence of resistance during mupirocin treatment: is it a problem in clinical practice?, f Chemother. (1999) 11(5):331–337.
   Google Scholar
• KAUFFMAN CA, TERPENNING MS, HE X et al.: Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am. J. Med. (1993) 94(4):371–378.
   PubMedGoogle Scholar
• SPICER WJ: Three strategies in the control of staphylococci including methicillin-resistant Staphylococcus aureus. Hasp. Infect. (1984) 5 (Suppl. A):45–49.
   Google Scholar
• Report of a combined working party of the British Society for Antimicrobial Chemotherapy, the Hospital Infection Society and the Infection Control Nurses Association. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. J. Hasp. Infect. (1998) 39:253–290.
   PubMed Web of Science ®Google Scholar
• LOEB M, MAIN C, WALKER-DILKS C, EADY A: Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst. Rev (2003) (4):CD003340.
   Google Scholar
• •An excellent evidence-based review.
   Google Scholar
• KNAUER A, FLADERER P, STREMPFL C, KRAUSE R, WENISCH C: Effect of hospitalization and antimicrobial therapy on antimicrobial resistance of colonizing Staphylococcus epidermidis. Wien. KIM Wochenschr. (2004) 116(14):489–494.
   PubMedGoogle Scholar
• TURNIDGE J, COLLIGNON P: Resistance to fusidic acid. Int./. Antimicrob. Agents (1999) 12 (Suppl. 2):535–544.
   Google Scholar
• DOBIE D, GRAY J: Fusidic acid resistance in Staphylococcus aureus. Arch. Dis. Child. (2004) 89(1):74–77.
   PubMedGoogle Scholar
• ••Currently the defmitive review of fusidicacid-resistant S. aureus.
   Google Scholar
• BESIER S, LUDWIG A, BRADE V, WICHELHAUS TA: Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mal Microbial (2003) 47(2):463–469.
   PubMedGoogle Scholar
• BROWN EM, WISE R: Fusidic acid cream for impetigo. Fusidic acid should be used with restraint. Br. Med. 1 (2002) 324(7350):1394.
   Google Scholar
• NISHIJIM S, OHSHIMA S, HIGASHIDA T, NAKAYA H, KUROKAWA I: Antimicrobial resistance of Staphylococcus aureus isolated from impetigo patients between 1994 and 2000. Int. J. Dermatol (2003) 42 (1) : 23–25.
   PubMedGoogle Scholar
• KESAH C, BEN REDJEB S, ODUGBEMI TO et al.: Prevalence of methicillin-resistant Staphylococcus aureus in eight African hospitals and Malta. Clin. Microbial Infect. (2003) 9(2):153–156.
   PubMedGoogle Scholar
• KIM HB, JANG HC, NAM HJ et al: In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey. Antimicrob. Agents Chemother. (2004) 48(4):1124–1127.
   PubMedGoogle Scholar
• OSTERLUND A, EDEN T, OLSSON-LILJEQUIST B et al.: Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid. Scand. J. Infect. Dis. (2002) 34(10):729–734.
   PubMed Web of Science ®Google Scholar
• TVETEN Y, JENKINS A, KRISTIANSEN BE: A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in Norway. I Antimicrob. Chemother. (2002) 50(6)873–876.
   Google Scholar
• O'NEILL AJ, LARSEN AR, HENRIKSEN AS, CHOPRA I: A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob. Agents Chemother. (2004) 48(9)3594–3597.
   Google Scholar
• •An important paper.
   Google Scholar
• MASON BW, HOWARD AJ, MAGEE JT: Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing. 1. Antimicrob. Chemother. 0003) 51(01033–1036.
   Google Scholar
• MASON BW, HOWARD AJ: Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study. Int. J. Antimicrob. Agents. (2004) 23(3):300–303.
   PubMedGoogle Scholar
• WILKINSON JD: Fusidic acid in dermatology. BE J. Dermatol (1998) 139\(Suppl. 53):37–40.
   Google Scholar
• SHAH M, MOHANRAJ M: High levels of fusidic acid-resistant Staphylococcus aureusin dermatology patients. BE J. Dermatol (2003) 148(5):1018–1020.
   PubMedGoogle Scholar
• SULE O, BROWN N, BROWN DF, BURROWS N: Fusidic acid cream for impetigo. Judicious use is advisable. BE Med. J. (2002) 324(7350):1394.
   PubMedGoogle Scholar
• STODDART B, COLLYNS T, DENTON M: Fusidic acid cream for impetigo. Problem may be clinically important. BE Med. J. (2002) 324(7350):1394.
   PubMedGoogle Scholar
• RAVENSCROFT JC, LAYTON A, BARNHAM M: Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin. Exp. Dermatol (2000) 25(4):327–330.
   PubMedGoogle Scholar
• EL-ZIMAITY D, KEARNS AM, DAWSON SJ, PRICES, HARRISON GA: Survey, characterization and susceptibility to fusidic acid of Staphylococcus aureus in the Carmarthen area. 1. Antimicrob. Chemother. (2004) 54(2):441–446.
   Google Scholar
• AXELSSON I. Treatment of impetigo: save mupirocin. BE Med. 1 (2004) 329(7472)979.
   Google Scholar
• ZAKRZEWSKA-BODE A, MUYTJENS HL, LIEM KD, HOOGKAMP-KORSTANJE JA: Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters. J. Hosp. Infect. (1995) 31(3):189–193.
   PubMedGoogle Scholar
• MOY JA, CALD WELL-BROWND, LIN AN, PAPPA KA, CARTER DM: Mupirocin-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa../. Am. Acad. Dermatol (1990) 22(5 Pt 1):893–895.
   Google Scholar
• LESKI TA, GNIADKOWSKI M, SKOCZYNSKA A, STEFANIUK E, TRZCINSKI K, HRYNIEWICZ W: Outbreak of mupirocin-resistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. I Clin. Microbic] (1999) 37(9):2781–2788.
   PubMedGoogle Scholar
• SCHMITZ FJ, LINDENLAUF E, HOFMANN B et al.: The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J.Antimicrob. Chemother. (1998) 42(4):489–495.
   PubMed Web of Science ®Google Scholar
• DESHPANDE LM, FIX AM, PFALLER MA, JONES RN; SENTRY Antimicrobial Surveillance Program Participants Group: Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn. Microbial. Infect. Dis. (2002) 42 (4): 283–290.
   PubMed Web of Science ®Google Scholar
• KOTRA L, SAMAMA J, MOBASHERY S: Beta-lactamases and resistance to beta-lactam antibiotics. In: Bacteria] resistance to antimicrobials. KS Lewis, AA Taber, HW Wax, RG (Eds), Marcel Decker, New York, NY, USA (2002) 123–160.
   Google Scholar
• •A useful update on bacterial resistance.
   Google Scholar
• SAMAHA-KFOURY J, ARAJ G: Recent developments in beta lactamases and extended spectrum beta lactamases. Br. Med. J. (2003) 327:1209–1213.
   PubMed Web of Science ®Google Scholar
• DUCKWORTH G: Controlling methicillin resistant Staphylococcus aureus. Br. Med. J. (2003) 327(7425):1177–1178.
   PubMedGoogle Scholar
• •Concise editorial on the control of MRSA.
   Google Scholar
• HRYNIEWICZ W: Epidemiology of MRSA. Infection (1999) 27\(Suppl. 2):513–516.
   Google Scholar
• YAMAGUCHI T, YOKOTA Y, TERAJIMA J et al: Clonal association of Staphylococcus aureus causing bullous impetigo and the emergence of new methicillin-resistant clonal groups in Kansai district in Japan. J. Infect. Dis. (2002) 185(10):1511–1516.
   PubMed Web of Science ®Google Scholar
• GOSBELL IB: Methicillin-resistant Staphylococcus aureus impact on dermatology practice. Am. J. Clin. Dermatol (2004) 5(4):239–259.
   PubMedGoogle Scholar
• BAGGETT HC, HENNESSY TW, LEMAN R et al.: An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect. Control. Hosp. Epidemiol (2003) 24(6):397–402.
   PubMedGoogle Scholar
• MUNCKHOF WJ, KLEINSCHMIDT SL, TURNIDGE JD: Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus an in vitro study. Int. 1. Antimicrob. Agents. (2004) 24(6):605–608.
   Google Scholar
• PERRY CM, JARVIS B: Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs (2001) 61(4):525–551.
   PubMed Web of Science ®Google Scholar
• STEVENS DL, HERR D, LAMPIRIS H et al.: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. (2002) 34(11):1481–1490.
   PubMed Web of Science ®Google Scholar
• SCHWEIGER ES, SCHEINFELD NS, TISCHLER HR, WEINBERG JM: Linezolid and quinupristin/dalfopristin: novel antibiotics for Gram-positive infections of the skin. .1 Drugs Dermatol (2003) 2(4):378–383.
   Google Scholar
• SCHWEIGER ES, WEINBERG JM: Novel antibacterial agents for skin and skin structure infections. J. Am. Acad. Dermatol (2004) 50(3):331–340.
   PubMed Web of Science ®Google Scholar
• ••Excellent recent review of latest therapiesfor cutaneous infections.
   Google Scholar
• HURDLE JG, O'NEILL AJ, CHOPRA I: Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. J. Antimicrob. Chemother. (2004) 54(2):549–552.
   PubMedGoogle Scholar
• •An important paper on recent advances.
   Google Scholar
• CUTLER RR, WILSON P: Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant Staphylococcus aureus. BE J. Biomed. Sci. (2004) 61(2):71–74.
   PubMed Web of Science ®Google Scholar
• SATO M, TANAKA H, YAMAGUCHI R, KATO K, ETOH H: Synergistic effects of mupirocin and an isoflavanone isolated from Erythrina variegata on growth and recovery of methicillin-resistant Staphylococcus aureus. Int. I Antimicrob. Agents. (2004) 24(3):241–246.
   PubMedGoogle Scholar
• DRYDEN MS, DAILLY S, CROUCH M: A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J. Hosp. Infect. (2004) 56(4):283–286.
   PubMedGoogle Scholar
• AL-SULAMI AA, AL-RUBIAY KK, AFFAT AM: An inhibitor of Staphylococcus aureus exfoliative toxin. East Mediterr. Health J. (2001) 7(1-2):121–127.
   PubMedGoogle Scholar
• COYLE EA: Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy (2003) 2 3 (5) : 6 3 8–6 4 2
   Google Scholar
• CIFTCI E, GURIZ H, AYSEV AD: Mupirocin versus terbinafine in impetigo. Indianj Pediatr. (2002) 69(8):679–682.
   Google Scholar